drugset / Trial / NCT05440227
PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients
RandomizedParallel-groupTriple-blindTreatment
Summary
The objective of this study is to assess the efficacy of weekly PG2 regimen as a complementary treatment for patients with recurrent unresectable (local or regional) or metastatic breast cancer who experienced moderate to severe fatigue while receiving chemotherapies.
Timeline
- Start
- 2023-05-17
- Primary completion
- 2025-12
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PG2 | Unknown | 500 mg | — |
Indications
No indication recorded.